-
Severe acute respiratory syndrome (SARS) is a novel viral epidemic which spread to more than thirty countries in 2003 and severely threatened worldwide public health. The clinical symptom of SARS is characterized by fever, dyspnoea, lymphopenia, and rapidly progressing changes observed by radiography. Its pathogen has been affirmed to be a novel coronavirus, SARS coronavirus (SARS-CoV), which established a solid bases for effective control and ultimate eradication of the disease (3, 4, 8, 9). The genomes of SARS-CoV has been mapped and some important structural and functional proteins have been determined, but many features regarding the noso-genesis, the antigenicity and the immuogenicity of SARS-CoV still remain indistinct (2, 7, 10, 17).
Vaccines play a crucial role in the control of infectious diseases. Previous experiences on human antiviral vaccines indicated that inactivated vaccines are much easier to develop and hold more potential. To investigate a SARS inactivated vaccine, effec-tiveness and safety of vaccine are two important aspects. Our efforts have focused on the investigation of the immunogenicity and safety of inactivated SARS-CoV on animals such as mice, rabbits, pigs, and horses (15, 16). This paper reports the specific antibody kinetics and the histopathological changes in rabbits immunized with inactivated SARS-CoV, which a view to gaining some insight towards the develop-ment of SARS inactivated vaccine.
HTML
-
SARS-CoV F69 strain (GenBank AY313906) was isolated from the samples of a onset of SARS patient in Guangdong province, China in 2003, and was screened out as the vaccine strain (5, 18). Vero E6 cells were cultivated routinely with MEM medium con-taining no bovine serum, followed by infection with F69 strain virus. After the cytopathic effect (CPE) reached more than 75%, the cell suspension was frozen and thawed three times, and stored at –70℃. The titer of virus suspension was 106.7 TCID50/mL determined with micro-plate CPE method.
-
Large-scale cultivated F69 virus suspension was inactivated with 0.4% formaldehyde (v/v) for 24 h at 37℃, and the inactivation efficiency (100%) was precisely identified (6). After centrifugation at 4 000× g for 30 min to remove precipitate, the virus supernatant was collected and purified by concentrating and gel permeation chromatography, then stored at –70℃ as the immunogen for animal immunization. The protein concentration of the prepared vaccine was 0.8 mg/mL.
-
Adult New Zealand rabbits (male, 2.0-2.5 kg) were randomly divided into 3 groups (n=4): the experi-mental group (G1, immunized with vaccine + adjuvant), the adjuvant group (G2, immunized just with adjuvant), and the control group (G3, injected with 0.9% NaCl sulution). Rabbits all were inoculated 3 times. The immune protocol was shown in Table 1. Eight batches of blood were sampled from the auricular vein at day 7, 14, 21, 28, 35, 38, 42 and 51. Serum was separated by centrifugation at 2 500×g for 10 min and stored at –20℃.
Table 1. Rabbit immunization protocol
-
The titer of serum specific IgG antibody was measured by indirect enzyme-linked immunosorbent assay (EL-ISA). A 96-wells microtiter plate was coated with inactivated SARS-CoV dilution (containing 1.0 µg/ mL total virus proteins). Then 2-fold serial serum dilutions were added (100 µL/well) and incubated at 37℃ for 60 min. The plate was washed with PBST, HRP-conjugated goat-anti-rabbit IgG antibodies (1:1000 dillution, Sino-American Biotech) were added (100 µL/well), and incubated at 37℃ for 60 min. The plate was washed, then OPD substrate (O-pheny-lendiamine, Sigma) was added (100 µL/well) and incubated at 37℃ for 20 min. The reaction was stopped with 2.0 mol/L sulfuric acid and the absorbance at 490 nm (A490) was measured by a microplate reader. In this assay, normal serum was used as negative control, and a positive antiserum was included in each plate as an inter-plate variability control. Antibody titer was defined as the highest dilution of serum at which the A490 ratio (A490 of sample / A490 of negative control) was greater than 2.0.
-
Neutralizing antibody titer was determined by the micro-cytopathic effect (CPE) neutralizing test ac-cording to the modified protocol for polio antibodies (13). The serum was diluted into two-fold serial dilutions with MEM maintenance medium, then mixed with an equal volume of 100 TCID50 active SARS-CoV and incubated at 37℃ for 60 min. After neutralization, the pretreated mixtures were succes-sively added into Vero E6 cell monolayers in a microtiter plate (100 µL/well); wells for normal cell control were added into 100 µL maintenance medium, and wells for virus control were added into unneu-tralized virus. The plate was incubated at 37℃ in 5% CO2 incubator, and cell status was monitored by SARS-CoV CPE every 24 h, until all wells of the virus control showed CPE but the cell control remained normal. Neutralizing antibody titer was defined as the highest dilution of serum which protected 50% of the cultures against CPE.
-
Antiserum samples were sent to Shanghai Health-Digit Biotech Ltd (11) for antibody specificity deter-mination with a special SARS protein chip system based on specific antigen-antibody interactions. Recombinant antigenic SARS-CoV proteins-M, N, E, 3CL and four segments of S protein were immobilized on a solid matrix. Diluted mice serum was added into the chip and incubated for 30 min at 37℃. After washing, specific enzyme-conjugated antibodies and tracer-marked substrates were added and incubated at 37℃. Finally, the developed chemiluminescent light signals were captured, digitized and analyzed by a chip reader.
-
On day 51 after the first vaccination, all the rabbits were sacrified, then autopsied to gain the lung, liver, heart, spleen, kidney and testis. Tissues of the sampled organs were fixed in 10% neutral-buffered formalin and routinely processed for paraffin embedding. Serial 4μm sections were cut from each block. The tissue slices were stained with hemotoxylin and eosin dyes (H & E), and detected with photomicrography.